Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MSH2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MSH2 Recombinant Protein (Full-Length / Domain Specific) High purity (>90% by SDS-PAGE), Endotoxin controlled. Sequence Verified. Suitable for biochemical binding and ATPase assays. |
View MSH2 Products |
| Gene Delivery | MSH2 Promise-ORF / Lentivirus Particles Full-length human MSH2 ORF for stable overexpression or rescue studies in mismatch repair (MMR) deficient models. |
View MSH2 Products |
| Benchmark Ab | Anti-MSH2 Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and immunoprecipitation assays. |
View MSH2 Products |
| Validator | MSH2 siRNA Set Target-specific siRNA pool for transient knockdown to validate MMR-deficiency phenotypes and synthetic lethal interactions. |
View MSH2 Products |
| Related Target A | MSH6 Obligate heterodimer partner of MSH2 forming the MutSα complex, essential for mismatch repair pathway assays. |
View MSH6 Products |
| Related Target B | POLQ (DNA Polymerase Theta) Key synthetic lethal target in MSH2-deficient/MSI-H tumors; target for combination therapy screening. |
View POLQ Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability (MSH2/MSH6 complex reconstruction) | Co-expressed or highly purified individual subunits with verified sequence integrity and theoretical molecular weight confirmation. |
| Low-Endotoxin Requirements for Cell Assays | Strictly controlled endotoxin levels (<1.0 EU/μg) to prevent non-specific immune activation in cell-based assays. |
| Lack of Controls | Clinical-grade recombinant benchmark antibodies included for assay standardization. |
| False Positives in Knockdown Screens | Sequence-verified siRNA pools with high knockdown efficiency to ensure target specificity. |
Live MSH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the DNA mismatch repair (MMR) pathway is undergoing a significant paradigm shift. MSH2, traditionally utilized as a diagnostic immunohistochemistry (IHC) biomarker to identify Lynch syndrome and Microsatellite Instability-High (MSI-H) colorectal, endometrial, and gastric cancers, is now emerging as a focal point for active therapeutic intervention.
Rather than direct inhibition of MSH2, current clinical strategies predominantly exploit MSH2 deficiency through synthetic lethality. MSH2-deficient tumors exhibit extreme sensitivity to double-strand break repair inhibitors (such as PARP inhibitors) and emerging targets like Polymerase Theta (POLQ) and Werner Syndrome Helicase (WRN). Simultaneously, research into small-molecule inhibitors of the MSH2-MSH6 ATPase activity is gaining traction to transiently induce an MSI-H phenotype, thereby sensitizing proficient tumors to immune checkpoint blockades (anti-PD-1/PD-L1).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Synthetic Lethal Small Mol (POLQ/WRN) | Artios Pharma, IDEAYA Biosciences | MSI-H Solid Tumors, Colorectal Cancer | Stable MSH2-knockout/knockdown cell lines (Lentivirus/siRNA validation) |
| Direct MSH2-MSH6 Inhibitors | Academic Spin-offs, Biotech Startups | MSS (Mismatch Repair Proficient) Tumors | Active MSH2/MSH6 recombinant protein complex for ATPase assays |
| Diagnostic & Companion IHC | Roche (Ventana), Agilent (Dako) | Lynch Syndrome, Endometrial Cancer | High-specificity recombinant benchmark antibodies for IHC calibration |